Wow, that's very close to the 90% I arrived at after a detailed analysis.I will share my analysis at some point, but suffice to say it's very unlikely Neuren won't get at least one new FDA approved treatment from NNZ-2591, and most likely they will get many. In the world of drug development NNZ-2591, for a whole list of reasons, is as close to a sure thing as it's possible to get.There was definite risk before the Trofinetide Phase 3 results.But for NNZ-2591 I am personally very relaxed. The risk of failure is low.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.10 |
Change
-0.800(5.76%) |
Mkt cap ! $1.629B | |||
| Open | High | Low | Value | Volume |
| $13.95 | $13.96 | $12.88 | $9.534M | 725.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 266 | $13.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.15 | 1619 | 2 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |